Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) EBITDA (2023 - 2025)

Historic EBITDA for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$51.5 million.

  • Zenas BioPharma's EBITDA fell 3315.91% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.0 million, marking a year-over-year decrease of 4725.74%. This contributed to the annual value of -$156.8 million for FY2024, which is 32334.13% down from last year.
  • As of Q3 2025, Zenas BioPharma's EBITDA stood at -$51.5 million, which was down 3315.91% from -$52.5 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's EBITDA ranged from a high of $35.6 million in Q3 2023 and a low of -$52.5 million during Q4 2024
  • For the 3-year period, Zenas BioPharma's EBITDA averaged around -$31.5 million, with its median value being -$37.9 million (2024).
  • As far as peak fluctuations go, Zenas BioPharma's EBITDA plummeted by 20853.24% in 2024, and later crashed by 2111.8% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's EBITDA stood at -$24.7 million in 2023, then plummeted by 112.62% to -$52.5 million in 2024, then increased by 1.89% to -$51.5 million in 2025.
  • Its EBITDA stands at -$51.5 million for Q3 2025, versus -$52.5 million for Q2 2025 and -$33.6 million for Q1 2025.